Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Reforms to Mergers and Acquisitions Disclosure and Evaluation Requirements in Korea

Treasury Shares as % of Total Outstanding Shares: Screening for Potential Activist Candidates

Korean Government to Announce Specific Measures to Increase Value of Low PBR Stocks in February

44% of Korean Stocks Are Trading Below Book Value - FSC Wants to Improve This (Following Japan)

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Cross Asset Strategy

<ul>
<li>On 4 February, numerous local media mentioned that there is an increasing probability of the Korean financial authorities introducing poison pill in order to improve corporate governance and M&amp;A reforms.</li>
<li>The main purpose of the poison pill would be to increase shareholder value, encourage the management to focus on investment and employment, and effectively defend itself against M&amp;A attempts.</li>
<li>Poison pill could have positive impact on companies with high levels of treasury shares and preferred shares. The uncertain outcome of National Assembly election in April remains a key risk. </li>
</ul>


On 4 February, numerous local media mentioned that there is an increasing probability of the Korean financial authorities introducing poison pill in order to improve corporate governance and M&amp;A reforms.
The main purpose of the poison pill would be to increase shareholder value, encourage the management to focus on investment and employment, and effectively defend itself against M&amp;A attempts.
Poison pill could have positive impact on companies with high levels of treasury shares and preferred shares. The uncertain outcome of National Assembly election in April remains a key risk. 


Korea M&A Reforms: Considering on Adopting Poison Pill in 2024